
Concerns Over Political Opposition to mRNA Vaccine Innovation
The article discusses the recent shift in U.S. policy under HHS Secretary Kennedy to reduce investment in mRNA vaccine technology, which was pivotal in COVID-19 response, citing safety concerns and strategic priorities. Experts warn this move could weaken the U.S.'s biosecurity and global competitiveness, as other countries like China continue to invest heavily in mRNA research, potentially leaving the U.S. dependent on foreign technology in future pandemics.



